Revolution Medicines Presents Overall Survival Data for RASONQUEÂ Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
Revolution Medicines' RASONQUE) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUEÂ Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUEÂ in Metastatic Non-Small Cell Lung Cancer
U.S. FDA Approves Revolution Medicines' RASONQUE , the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026Â
Brixton Metals Announces Upsize of Previously Announced Non-Brokered Private Placement to $8 Million and Closing of Second Tranche
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
